Soleno Therapeutics Inc
SLNO80.320USD
-8.170-9.23%
收盘 07/10, 16:00（美东）报价延迟15分钟
3.67B总市值
亏损市盈率 TTM
关于 Soleno Therapeutics Inc 公司
Soleno Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发和商业化用于治疗罕见疾病的新型疗法。其主要候选药物二氮嗪胆碱缓释片 (DCCR) 是一种缓释片，是一种用于治疗普拉德-威利综合征 (PWS) 的每日一次口服药，最近完成了其第 3 阶段开发计划。DCCR 是一种有效的 ATP 敏感钾 (KATP) 通道激活剂。DCCR 片剂含有活性成分二氮嗪胆碱，二氮嗪是一种苯并噻二嗪类药物的胆碱盐。DCCR 的作用模式是针对大脑、胰腺和脂肪组织，有可能影响 PWS 等复杂疾病，以减少食欲、减少食物寻求、提高饱腹感、改善胰岛素和瘦素抵抗并减少体脂。该公司在美国和欧盟拥有 PWS 中 DCCR 的快速通道称号以及该药物的孤儿药称号。
公司简介
公司代码SLNO
公司名称Soleno Therapeutics Inc
上市日期Oct 23, 2014
成立日期1999
CEODr. Anish Bhatnagar, M.D.
员工数量92
证券类型Ordinary Share
年结日Oct 23
公司地址100 Marine Parkway, Suite 400
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编94065
电话16502138444
网址https://soleno.life/
公司代码SLNO
上市日期Oct 23, 2014
成立日期1999
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Meredith Manning
Ms. Meredith Manning
Chief Commercial Officer
Chief Commercial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
持股股东
持股股东
占比
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
33.33%
Hedge Fund
31.65%
Investment Advisor
26.64%
Venture Capital
12.54%
Private Equity
4.02%
Research Firm
2.73%
Individual Investor
1.92%
Bank and Trust
0.53%
Pension Fund
0.18%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
375
57.23M
113.56%
+142.75K
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
2023Q1
121
4.63M
57.04%
-249.13K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
5.14M
10.2%
-47.37K
-0.91%
Mar 31, 2025
Vivo Capital, LLC
4.46M
8.85%
-1.83M
-29.14%
Mar 31, 2025
Adage Capital Management, L.P.
4.39M
8.72%
+1.62M
+58.24%
Mar 31, 2025
Avoro Capital Advisors LLC
2.52M
5.01%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.37M
4.7%
+768.45K
+48.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.12M
4.21%
+1.36M
+179.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
3.69%
-18.21K
-0.97%
Mar 31, 2025
Nantahala Capital Management, LLC
1.76M
3.49%
-2.17M
-55.28%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
3.4%
-105.47K
-5.79%
Mar 31, 2025
Citadel Advisors LLC
1.58M
3.13%
+603.63K
+62.08%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Harbor Health Care ETF
2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
2.19%
SPDR S&P Biotech ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Direxion Daily S&P Biotech Bull 3X Shares
0.5%
JPMorgan Healthcare Leaders ETF
0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
0.3%
Fidelity Fundamental Small-Mid Cap ETF
0.21%
Optimize Strategy Index ETF
0.19%
BNY Mellon US Small Cap Core Equity ETF
0.15%
查看更多
Harbor Health Care ETF
占比2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
占比2.19%
SPDR S&P Biotech ETF
占比1.04%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.98%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.5%
JPMorgan Healthcare Leaders ETF
占比0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.3%
Fidelity Fundamental Small-Mid Cap ETF
占比0.21%
Optimize Strategy Index ETF
占比0.19%
BNY Mellon US Small Cap Core Equity ETF
占比0.15%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
公告日期
类型
比率
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
